---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000070"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-10-13T12:10:56+00:00"
generated_at: "2026-10-13T12:15:07.815174+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncolytics says new pelareorep method-of-use patents extend IP protection into late 2040s

## Summary
- New method-of-use patent covering pelareorep as a cancer immunotherapy issued in several countries; corresponding U.S. patent expected in the near term.
- Existing manufacturing patent protection runs through 2044; company targets extension into the late 2040s via new patents.
- Three patent application families pending, including multiple method-of-use filings covering pelareorep with immunotherapies and targeted therapies.
- Company expects to convert one pending application to a USPTO Track One prioritized examination this quarter, targeting final disposition in ~12 months.
- Working with an academic partner on 'next generation' modified pelareorep; a new composition of matter patent could add up to 20 years from filing, CEO Jared Kelly said.

## SEC filing metadata
- accession: 0001129928-26-000070
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-10-13T12:10:56+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/0001129928-26-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/oncy-20261012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000070
- JSON: https://secwatch.observer/filing/0001129928-26-000070.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.